ARCHIVES

Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest.

This article is from The Cancer Letter archive.

Vol. 32 No. 42 | November 22, 2006

Download PDF Visit The Full Archive

Related Articles

Program Announcement On Effects Of Low Dose Radiation

October 2, 1981

NCCS Networker Volume 6 Issue 1, Winter 1992

January 13, 1992

NCI-DOD Agreement Could Be Model For Similar Project With HCFA, Lee Says

March 8, 1996

Hematologic Malignancies: ASCO Meeting Highlights New Approaches To Treatment

July 30, 2004

White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.

September 30, 2005

ADT Does Not Raise Risk of Heart Attacks In Men With No History Of Heart Disease

November 25, 2011